News | August 29, 2025
Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial
Triggering global regulatory submissions this year for the treatment of obesity
Triggering global regulatory submissions this year for the treatment of obesity
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Delegates also visited Emami’s WHO-GMP-certified manufacturing plant and Zandu Foundation for Healthcare farms for hands-on exposure to quality practices,
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Guidelines aim to establish state-regulated veterinary blood banks
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
The company has improved access to quality healthcare for seniors across both urban and rural areas
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Subscribe To Our Newsletter & Stay Updated
